Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GF 1002

X
Drug Profile

GF 1002

Alternative Names: GF-1002

Latest Information Update: 06 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genflow Biosciences
  • Class Gene therapies; Hepatoprotectants
  • Mechanism of Action Gene transference; SIRT6 protein expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Non-alcoholic steatohepatitis

Most Recent Events

  • 01 Feb 2024 Genflow Biosciences plans a phase-I/II trial for Non-alcoholic steatohepatitis in Belgium in 2024
  • 20 Sep 2023 Preclinical trials in Non-alcoholic steatohepatitis in United Kingdom (IV)
  • 20 Sep 2023 Genflow Biosciences receives the receipt of written comments from the Federal Agency for Medicines and Health Products (FAHMP) to commence a phase I/II clinical trial for the treatment of non-alcoholic steatohepatitis (NASH) in Belgium
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top